Clinical research progress on the application of anti-vascular endothelial growth factors in the treatment of retinopathy of prematurity
10.3760/cma.j.cn101070-20240811-00507
- VernacularTitle:抗血管内皮生长因子治疗早产儿视网膜病变的临床研究进展
- Author:
Keyue LI
1
;
Juan DU
1
;
Mingyan HEI
1
Author Information
1. 国家儿童医学中心，首都医科大学附属北京儿童医院新生儿中心，北京 100045
- Publication Type:Journal Article
- Keywords:
Infant, newborn;
Retinopathy of prematurity;
Treatment;
Anti-vascular endothelial growth factor
- From:
Chinese Journal of Applied Clinical Pediatrics
2025;40(7):548-553
- CountryChina
- Language:Chinese
-
Abstract:
Retinopathy of prematurity (ROP) is a retinal vascular proliferative disease affecting premature and low birth weight infants, and it is a serious eye disease that can lead to blindness in children.The classic treatment for ROP is retinal laser photocoagulation.In recent years, with the attention paid to anti-vascular endothelial growth factor (VEGF) drug therapy, increasing evidence supports the efficacy of intravitreal injection of anti-VEGF drugs in the treatment of ROP.In this article, the mechanism of action, development progress, efficacy and safety of anti-VEGF drugs for ROP are reviewed.
